Low Density Lipoprotein (LDL) News and Research

RSS

Pivotal Therapeutics reports financial results for Q3 2013

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies announced its third quarter financial results and operational highlights for the three and nine months ended September 30, 2013.

30 Nov 2013

Drug interactions impact use of cholesterol-lowering statin drugs

A new study has found that many people who stopped taking cholesterol-lowering statin drugs were also taking an average of three other drugs that interfered with the normal metabolism of the statins.

27 Nov 2013

CVD expert requests Mexican government to carry out mandatory screening for 18-year-olds

A cardiovascular disease expert is calling for mandatory screening of 18 year-old Mexicans to halt the CVD epidemic plaguing the nation. Cardiovascular risk factors will be a key theme at the Mexican Congress of Cardiology, held 23 to 27 November in Leon, Guanajuato, Mexico. The Congress is organised by the Mexican Society of Cardiology and features a collaborative programme with the European Society of Cardiology.

23 Nov 2013

Patients better adhere to medication regimens following hospitalization for acute coronary syndrome

Patients better adhered to their medication regimens in the year following hospitalization for acute coronary syndrome when they were part of a program that included personalized attention from a pharmacist compared with usual care, according to a study by P. Michael Ho, M.D., Ph.D., of the Denver VA Medical Center, and colleagues.

19 Nov 2013

Researchers develop more accurate way to calculate "bad" cholesterol

Johns Hopkins researchers have developed a more accurate way to calculate low-density lipoprotein (LDL) cholesterol, the so-called "bad" form of blood fat that can lead to hardening of the arteries and increase the risk of heart attack and stroke.

18 Nov 2013

New method for estimating LDL-C levels more accurate than standard measure

Seth S. Martin, M.D., of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, and colleagues developed a method for estimating low-density lipoprotein cholesterol (LDL-C) levels that is more accurate than the standard measure.

18 Nov 2013

Study: Surgical weight loss may be able to reverse the effects of aging

Stanford University researchers say surgical weight loss may turn back the effects of aging at a genetic level, in the first study* of its kind presented here during ObesityWeek 2013, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity.

16 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

Artificial trans fatty acids not needed anymore

Artificial trans fatty acids are no longer needed in advanced technological societies, says metabolic disease expert Henry Pownall, Ph.D., a chemist who has been studying fatty acid and cholesterol metabolism for over four decades.

14 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Eliza's Star multi-modal programs address gaps in healthcare

Eliza Corporation ("Eliza"), the pioneer and recognized leader in Health Engagement Management, today announced "Star 2014", a proactive member communication solutions suite that addresses key areas of the Centers for Medicare & Medicaid Services (CMS) Star programs.

30 Oct 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

New study finds association between OSA and subclinical myocardial injury

Obstructive sleep apnea is known to be associated with an increased incidence of cardiovascular disease. Now a new study indicates that OSA is associated with subclinical myocardial injury, as indicated by increased high sensitivity troponin T levels. Elevated hs-TnT levels are predictive of both coronary heart disease and heart failure in the general population.

25 Oct 2013

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

Research from Boston University School of Medicine suggests that testosterone treatment in hypogonadal (testosterone deficient) men restores normal lipid profiles and may reduce the risk of cardiovascular disease. These finding currently appear online in the International Journal of Clinical Practice.

24 Oct 2013

FDA issues final approval for Lupin's sNDA for Antara capsules

Pharma Major Lupin Limited announced today that it has received final approval for its supplemental New Drug Application for Antara (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration.

23 Oct 2013

Hereditary high blood cholesterol overlooked and untreated worldwide

Hereditary high blood cholesterol leads to premature heart disease. It is overlooked and untreated virtually worldwide -- including in Europe. This is a major problem as the disease is dangerous for health. However, this disease is easy to diagnose and treat, according to the conclusion of a consensus report from the European Atherosclerosis Society.

21 Oct 2013

Researchers find 5-fold increase in high cholesterol risk

What leads to high cholesterol? Your genes and lifestyle factors may not explain it all. A study presented today at the Canadian Cardiovascular Congress has connected some of the risk for high cholesterol in adults to their mother's cholesterol levels before she even became pregnant.

17 Oct 2013

Research shows inhibition of Rcan1 protein may reduce atherosclerosis in mice

Researchers of the Spanish research council (Consejo Superior de Investigaciones Cient-ficas, CSIC) and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that inhibiting the protein Rcan1 in mice reduces the burden of atherosclerosis, one of the commonest cardiovascular diseases.

16 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

Men who didn't exercise more likely to have dysfunctional HDL

There's no question that high levels of good cholesterol-also known as high-density lipoprotein -seem to be protective against heart disease. Rather than depositing fat into the blood vessels the way the "bad" cholesterol (low-density lipoprotein does, HDL appears to carry cholesterol away from blood vessels to the liver. From there, the liver processes it for removal from the body.

13 Oct 2013